Wednesday, July 8, 2026

Patent intelligence · US

US 9353069

Super-oxide dismutase mimetics

granted A61KA61K31/395A61K31/4353A61K31/555
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 10
Applicant portfolio 23
Patent details — US 9353069
Jurisdiction
US
Status
granted
Grant date
May 31, 2016
Expiration
May 26, 2036
Applicant
Galera Labs, LLC
Claims
21
CPC classes
A61K, A61K31/395, A61K31/4353, A61K31/555
View on Google Patents ↗

Quick answer

US 9353069 (Super-oxide dismutase mimetics) is held by Galera Labs, LLC. Status: granted. Granted May 31, 2016. Expires May 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Galera Labs, LLC
Grant date
Expiration
Claims
21
CPC classes
A61K, A61K31/395, A61K31/4353, A61K31/555, A61P, A61P11/06

More from Galera Labs, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12220420

    Combination therapy for cancer treatment

    Galera Labs, LLC · Expires Feb 6, 2045

    granted
  2. US 12156863

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Expires Nov 28, 2044

    granted
  3. US 12077549

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Galera Labs, LLC · Expires Aug 29, 2044

    granted
  4. US 11826373

    Methods for treatment of diseases

    Galera Labs, LLC · Expires Nov 23, 2043

    granted
  5. US 11612608

    Methods of treating oral mucositis

    Galera Labs, LLC · Expires Mar 23, 2043

    granted
  6. US 11246950

    Combination cancer immunotherapy with pentaaza macrocyclic ring complex

    Galera Labs, LLC · Expires Feb 10, 2042

    granted
  7. US 11219614

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Expires Jan 6, 2042

    granted
  8. US 11066433

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Galera Labs, LLC · Expires Jul 15, 2041

    granted

Frequently asked questions

What is US patent 9353069?

US 9353069 (Super-oxide dismutase mimetics) is held by Galera Labs, LLC. Status: granted. Granted May 31, 2016. Expires May 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9353069?

Galera Labs, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.

When does US 9353069 expire?

Our index shows an expiration date of May 26, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.